Table I.
Patient Characteristics
| Variables | N (%) |
|---|---|
| N | 33 |
| Median age, years (range) | 62 (27 – 83) |
| Sex | |
| Female | 9 (27) |
| Male | 24 (73) |
| Karnofsky performance score | |
| 70 | 5 (15) |
| 80–100 | 28 (85) |
| Diagnosis | |
| PTCL-NOS | 21 (64) |
| AITL | 8 (24) |
| ALCL, T- and null cell types | 4 (12) |
| Ann Arbor Stage | |
| II | 4 (12) |
| III | 9 (27) |
| IV | 20 (61) |
| B symptoms | |
| No | 18 (55) |
| Yes | 15 (45) |
| IPI Score | |
| Low | 9 (27) |
| Low – intermediate | 9 (27) |
| High – intermediate | 9 (27) |
| High | 6 (19) |
| Lactate dehydrogenase | |
| Normal | 17 (52) |
| Elevated | 16 (48) |
| Extranodal involvement | |
| 0–1 | 24 (73) |
| 2 or more | 9 (27) |
| Median number of chemotherapy cycles (range) | 4 (1–6) |
| Median follow-up of survivors, months (range) | 20.4 (11.9 – 31.2) |
PTCL-NOS, peripheral T-cell lymphoma, not otherwise specified; AITL, angioimmunoblastic T-cell lymphoma; ALCL, anaplastic large cell lymphoma; IPI, International Prognostic Index.